Oral and monthly shots for HIV control in children
Part of Infections clinical trials.
This trial studies whether a child can safely move from HIV medicine taken by mouth to long-acting monthly injections. It looks at keeping HIV levels suppressed (very low) and monitoring side effects and safety over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is age 2 to under 12 years, and weighs 10 to under 40 kg
- You can bring your child to the study visits on schedule and follow study rules
- Child has confirmed HIV infection and has been on the same HIV medicines for at least 6 months
- Child’s HIV blood test shows HIV is controlled (very low) near enrollment
- Child’s key blood tests are in acceptable ranges at screening
- Child does not have evidence of hepatitis B infection based on blood test results
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a long-acting injection called lenacapavir for children and teens with HIV who have tried other treatments and still have detectable virus. It may be an option if current medicines aren't working well enough.
This trial tests if switching to a long-acting injectable medication can help people with HIV who have trouble keeping their virus suppressed with daily pills. You would receive shots in the buttocks every few months instead of taking pills every day.
This study tests whether a combination of two long-acting HIV medications (cabotegravir and rilpivirine), given as shots every month, is safe and works well for pregnant women who are already taking this treatment. It aims to keep the mother's HIV under control and protect the baby.
This trial tests a new antibody medication given as a shot to babies with HIV. It aims to help control the virus and may be an option for infants who are newly diagnosed or starting treatment.
This trial tests a new ultra-long-acting injectable combination of cabotegravir and rilpivirine for people with HIV who already have the virus under control. It aims to see if these shots can keep the virus suppressed with fewer doses.
This study tests a new long-acting medicine that may help prevent HIV. It is given as an injection, and the study checks how safe it is and how it works in healthy volunteers.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.